As we prepare to enter the next decade of this revolutionary law, we cordially invite you to join us for ACI’s 11th Annual Biosimilars Summit.

As the number of FDA-approved biosimilar products continues to grow,the need for a solid guiding framework becomes more critical than ever before.  While the stakeholders wait for finality on the rules governing significant matters like interchangeability, substitution and equivalency, it is clear that biosimilars will remain a top priority for the FDA.

The biosimilars market continues to maintain momentum as we head into 2020, but questions remain as to whether the U.S. market will catch up with Europe and whether biosimilars will provide their intended cost-savings.

Join the “who’s who” of the biosimilars and innovator biologics industries as they gather in New York for ACI’s 2020 Summit on Biosimilars, and contemplate these and other probing questions.

Sign up and stay tuned for more exciting programming announcement and our incredible speaker line-up!

Thank You to Our Esteemed 2019 Biosimilars Co-Chairs

Immac “Casey” Thampoe

Executive Director/Assistant General Counsel
IP Portfolio Development

Regeneron Pharmaceuticals, Inc.

 Year after year, the ACI Biosimilar Conference has featured a top-notch faculty from the pharma/biotech industry, private practice and government to address hot-button issues in this rapidly evolving area — I am looking forward to another outstanding event.  

Charles K. Sholtz

Director and Associate General Counsel
Biosimilars, Manufacturing & Litigation Readiness Lead

Genentech

 If I had to pick only one event to get the latest on issues impacting biosimilars, it would be the ACI Biosimilar Conference — highly informative presentations and ample opportunities to network and catch-up with players in this space.  

 
 

SAMPLE PAST IN-HOUSE ATTENDANCE

Acceleron Pharma
Aceto Corporation
Acorda Therapeutics
Actavis Generics
Adello Biologics
Alder Biopharmaceuticals
Alexion Pharmaceuticals
Alkermes
Allergan
Alvogen
Amgen
Apotex Corporation
Astrazeneca
Athersys Inc
Barr Laboratories
Bausch & Lomb Inc
Baxter Healthcare Corp
Bayer HealthCare
Bedford Laboratories
Ben Venue Laboratories
Biogen
BioMarin Pharmaceutical
Boehringer Ingelheim GmbH
Bristol-Myers Squibb
BRM Biopharm Source LLC
Celgene Corporation
Celltrion Inc
Centocor Inc
Cerulean Pharma Inc
Chemo Espana
ChemWerth Inc
Chiesi
Coherus Biosciences Inc
Cornerstone Research
Daiichi Sankyo Co

DaVinci Healthcare
Dr. Reddy’s Laboratories
Eisai Inc
Elan Pharmaceuticals Inc
Eli Lilly & Company
EMD Serono Inc
Endo Pharmaceuticals Inc
Fresenius Kabi USA
Fresenius Kabi Deutschland GmbH
Gan & Lee Pharmaceuticals
Gedeon Richter Pharma GmbH
Gene Techno Science Co
Genentech
Genzyme
Gilead Sciences
Glaxosmithkline Plc
Glenmark Pharmaceutical
Glycobia
GSK
GTC Biotherapeutics Inc
Hikma Pharmaceuticals
Hoffmann-La Roche
Hospira Inc
ImClone Systems Incorporated
Immunogen Inc
Johnson & Johnson
Jounce Therapeutics
Kashiv Biosciences LLC
LG Life Sciences
Lonza
Lupin Pharmaceuticals Inc
Medicago Inc
Medicines Company
MedImmune Inc AstraZeneca
Meitheal Pharmaceuticals

Merck & Co
Millennium Pharmaceuticals
Mitsubishi Tanabe Pharma Development America
Momenta Pharmaceuticals
Mylan
Neose Technologies
Novartis Oncology
Novo Nordisk
Paravid LLC
PDL Biopharma Inc
Progenity Inc
Pfizer Inc
Purdue Pharma LP
R-T Specialty LLC
Regeneron Pharmaceuticals
REGENXBIO Inc
Roche Inc
Samsung Bioepis Co Ltd
Sandoz Inc
Sanofi
Seattle Genetics Inc.
Shanghai Henlius Biotech Inc
Shionogi & Co Ltd
Shire Pharmaceuticals
Sunovion Pharmaceuticals Inc
Sutro Biopharma Inc
Takeda Pharmaceuticals
Teva Pharmaceutical
Turnstone Biologics Inc
UCB Inc
Vertical Pharmaceuticals Inc
Wyeth BioPharma
Zydus Research Centre


Don’t miss this opportunity to benchmark your biosimilar strategies with top industry representatives.
Register now and enjoy early bird savings!

WHO YOU WILL MEET:

  • In-house counsel from branded and biosimilars companies
  • Government representatives from the FDA, USPTO, and the Judiciary
  • Leading regulatory and patent attorneys from around the country

ACI’s Global Series of Life Sciences conferences bring together key sector stakeholders from around the globe to explore the most important trends impacting the many industries including pharmaceutical, biotechnology, medical device/diagnostics, and FDA-regulated consumer products. Our events cover every facet of legal and business relevance as well as controversy.
Learn More


Event Contacts

Sponsorship Opportunities:

American Conference Institute
Email Us

Media Partnership Opportunities:

Linda Lam
Email Us

Programme Information and Speaking:

Joseph Gallagher
Email Us